ReviewMedicine2025
Mucous membrane pemphigoid involving the upper respiratory tract: A case series and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleWe present a case series involving 4 patients diagnosed with upper respiratory tract mucous membrane pemphigoid (MMP) at a tertiary referral center, accompanied by a comprehensive literature review. PATIENT CONCERNS: This study focuses on cases of MMP that presented with respiratory symptoms and were treated at the Department of Otolaryngology-Head and Neck Surgery, West China Hospital, from 2018 to 2023. In addition, it reviews cases of MMP affecting the upper respiratory tract that have been published on PubMed from 2013 to 2023. DIAGNOSES: Four patients were diagnosed with MMP affecting the upper respiratory tract.
interventionsOne patient required a tracheotomy due to severe dyspnea, while the other 3 initially presented with symptoms affecting various regions of the upper respiratory tract. Diagnosis for 3 of the patients was confirmed through direct immunofluorescence of skin or mucosal samples, in conjunction with pathological examination, and they were subsequently treated with systemic glucocorticoids. OUTCOMES: Notably, the second patient exhibited favorable outcomes when glucocorticoids were combined with methotrexate. The third patient's condition showed gradual improvement following the initial glucocorticoid treatment, and intravenous immunoglobulin and rituximab were later administered to alleviate symptoms. Following the tracheotomy, the fourth patient's disease was effectively managed with regular corticosteroid treatment in the Dermatology Department. LESSONS: Considering the prevalent symptoms associated with upper respiratory tract MMP and the severe repercussions of failing to intervene, early diagnosis and the timely administration of systemic corticosteroids are of paramount importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.